Vorapaxar Sulfate
Vorapaxar sulfate is the sulfate salt form of vorapaxar, a PAR-1 thrombin receptor antagonist used for secondary prevention of thrombotic cardiovascular events. The sulfate salt provides the aqueous solubility needed for the oral tablet formulation. Like the free base, it irreversibly binds PAR-1 on platelets to reduce thrombin-induced platelet aggregation.
Molekularmasse
590,7000 g/mol
TPSA
161,00 Ų
Therapeutische Bereiche
Wirkmechanismus
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
2D-Struktur
Cite this structure
Embed this structure
SMILES
CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1.O=S(=O)(O)O
InChI
InChI=1S/C29H33FN2O4.H2O4S/c1-3-35-29(34)32-23-10-11-24-20(14-23)15-26-27(17(2)36-28(26)33)25(24)12-9-22-8-7-19(16-31-22)18-5-4-6-21(30)13-18;1-5(2,3)4/h4-9,12-13,16-17,20,23-27H,3,10-11,14-15H2,1-2H3,(H,32,34);(H2,1,2,3,4)/b12-9+;/t17-,20+,23-,24-,25+,26-,27+;/m1./s1
Molecular Formula
C29H35FN2O8S
HBD / HBA
3 / 10
Rotierbare Bindungen
6
Schwere Atome
41
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
Vorapaxar sulfate is the sulfate salt form of vorapaxar, a PAR-1 thrombin receptor antagonist used for secondary prevention of thrombotic cardiovascular events. The sulfate salt provides the aqueous solubility needed for the oral tablet formulation. Like the free base, it irreversibly binds PAR-1 on platelets to reduce thrombin-induced platelet aggregation.
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Yes, Vorapaxar Sulfate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2107386. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 10077129. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="vorapaxar-sulfate"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/vorapaxar-sulfate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/vorapaxar-sulfate/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/vorapaxar-sulfate/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="vorapaxar-sulfate"></drugfyi-drug>